Human-RJB-0402

Human-RJB-0402 is a liver-directed gene therapy candidate developed by Rejuvenate Bio for the treatment of metabolic and age-related diseases. The therapy is designed to deliver the gene encoding Fibroblast Growth Factor 21 (FGF21), a potent metabolic hormone that regulates glucose and lipid metabolism, enhances insulin sensitivity, and increases energy expenditure. By utilizing a gene therapy modality, Human-RJB-0402 aims to provide sustained, long-term expression of the FGF21 protein, overcoming the short half-life and frequent dosing requirements associated with recombinant FGF21 protein therapies. The program is currently in the human health pipeline at Rejuvenate Bio, leveraging their platform for epigenetic reprogramming and metabolic health.